The tumor suppressor gene p16 ink4a is homozygously deleted in numerous T as well as in some B lineage acute lymphoblastic leukemia (ALL). We therefore analyzed the clinical and biological implications of this feature by studying p16 ink4a expression in 58 cases of childhood ALL. mRNA and protein were significantly correlated and both appeared more highly expressed in B than in T lineage ALLs: 13 out of the 15 T cell ALLs did not show any p16 ink4a expression. The main result of this study is the strong prognostic value of p16 ink4a expression. When stratifying the patients in three groups according to p16 ink4a expression, we observed in univariate analysis: (1) the shortest disease-free survival for patients presenting a high p16 ink4a level; (2) contrasting with the good prognosis in the group of patients expressing p16 ink4a at low level; (3) while cases without any expression of the inhibitor were associated with a medium course of the disease (P = 0.0165). This prognostic value was confirmed by the multivariate analysis showing therapeutic regimen and p16 ink4a protein expression as the only variables retained in the model. A specific metabolic profile related to cellular survival and proliferation was observed in each of the three p16 ink4a expression groups. Among the cell cycle-related proteins we analyzed, only p21 waf1 bcl-2 and CDK4 were significantly and positively correlated to p16 ink4a . Furthermore, CDK6 was also strongly expressed in the group of cases with high p16 ink4a level. An enhancement of p16 ink4a , p21 waf1 and bcl-2 was previously described in prolonged cellular survival, while aging cells showed a decrease in CDK4 expression. The concomitant high expression of the oncogenic protein CDK4 (and of CDK6), we observed, may amplify the leukemic advantage of prolonged lifespan blast cells by favoring cell progression through G1 phase. These data suggest that at least two mechanisms may be associated in the oncogenesis of very aggressive ALLs, ie deregulation of cell multiplication and prolonged blast lifespan.
Introduction
The intra-cellular control of cell proliferation is mainly effected by a group of serine-threonine kinases associated, when active, with cyclins and called cyclin-dependent kinases (CDK). CDK4 (or CDK6) associated with cyclin D (D1, D2 or D3), their regulatory subunits, are involved in G1 progression. 1, 2 These kinases phosphorylate and inactivate the retinoblastoma susceptibility gene product (pRb), enabling cells to continue the cell cycle. The kinasic activity is mainly regulated by: (1) the association with cyclins; (2) several steps of phosphorylation and dephosphorylation; and (3) binding of specific inhibitors called CDK inhibitors (CKI).
3 p16 ink4a inhibits the kinasic activity of the CDK4 (or CDK6)/cyclin D enzymes and represents a major CKI for the G1 phase. p16 ink4a overexpression leads to a G1 arrest in the presence of a functional pRb. 5 When present in high levels, the inhibitor competes with D cyclins for binding to CDKs, which are sequestered in inactive protein complexes. 6 p16 ink4a mRNA is, at least in part, negatively controlled by pRb. However, it has also been shown that p16 ink4a mRNA and protein accumulate in senescent fibroblasts, and an apparent overexpression could be caused by an increase in the number of population doublings. 7 The INK4a gene was mapped to chromosome 9p21, and a high frequency of homozygous deletions or rearrangements of the p16 ink4a locus was reported in numerous human cancer cell lines, including leukemic cell lines. 8 Homozygous INK4a deletions are less frequent in primary leukemic cells than in cell lines, but may occur without any detectable cytogenetic changes in 9p. 9 This deletion is observed more frequently in T acute lymphoblastic leukemia (ALL) than in B lineage ALL. [10] [11] [12] [13] [14] [15] The comparison of clinical features at presentation in p16 ink4a −/− and in p16 ink4a germ line ALL cases showed a greater leukemic cell mass and a higher white blood cell count in the first group. 13 However, it is unlikely that p16 ink4a gene deletion could represent a clinically prognostic factor in childhood ALL. 14, 15 Results of treatment in childhood ALL remain incompletely satisfactory because of relapses observed even with high-dose chemotherapy. In order to better understand the regulation of mitotic activity of lymphoblastic cells in childhood ALL and its relationship to treatment outcome, we turned to the analysis of p16 ink4a mRNA and protein expression and their relationships to the other cell cycle regulatory or related proteins. We show the poor influence of an enhanced expression of p16 ink4a on prognosis and the possible linkage of a p16 ink4a high level to prolonged blast survival.
Materials and methods

Patients
Fifty-eight cases of childhood ALL were studied from January 1994 to July 1997. Thirty patients were male and 28 were female, with ages ranging from 0.24 to 17.95 years (median: 6.6). Cell samples were obtained, at diagnosis, from bone marrow aspiration in all cases. Selection for evaluation was based on the availability of cell sample; consequently, patients having high initial blast-cell counts are numerous in this study (WBC over 100 G/l in 26% cases). The ALLs were classified according to the French-American-British (FAB) recommendations 16 after cytological examination and cytochemical assays (peroxidase and naphthyl acetate esterase) as L1 (50 cases), L2 (five cases), L3 (one case) and unclassified (one case). All cell samples contained at least 80% blast cells. Mononuclear cells were isolated by Ficoll-Hypaque density gradient (d = 1.077) centrifugation. In all cases, immunolog- ical phenotype, cytogenetics and cell cycle variables were determined on cell suspension at diagnosis and a specimen of a neoplastic tissue was frozen at −80°C pending protein and mRNA studies. Immunological tumor cell phenotype was determined as previously described. 17 Lymphoblast populations were divided into four categories: (1) early early pre-B (CD10 − ) ALL (six cases), (2) early pre-B (CD10 + ) (33 cases) and pre-B-ALL (IgM + ) (three cases), (3) B ALL (one case) and (4) T-ALL (15 cases).
Chromosome analysis of bone marrow was performed in all cases by short-term cultures without phytohemaglutinin. Banding analysis was based on RHG banding. 20 banded metaphases were karyotyped per patient. A t(9;22)(q34;q11) translocation was observed in two cases and a t(4;11)(q21;q23) translocation in two other cases.
Patients were treated according to the EORTC 58881 CLCG trial 18 in the same institution (Debrousse Hospital, Lyon, France). Patients were stratified according to their risk factor. A so-called very high risk group (VHR) was defined by the presence of at least one of the following criteria regardless of the initial blast cell count: (1) blast cell count over 1 G/1 at the end of the glucocorticoid pre-treatment; (2) non-achievement of complete remission at the end of induction; (3) poor cytogenetic features, ie t(9;22), t(4;11), t(1;19) or near haploidy. A resistance to glucocorticoid was found in 16 cases. Thirty-five patients were treated with the standard risk schedule, 20 with the VHR protocol. Two patients received another treatment: the unique L3 ALL of this series, and a patient treated in another hospital. These two patients are alive, in complete remission. Follow-up could not be obtained for one patient, a Jehovah's Witness who did not accept treatment. Complete remission was obtained in all the 57 remaining treated cases. A relapse occurred in eight of these cases, two of them presented a poor cytogenetic feature (one t(9;22) and one t(4;11)). These medullary relapses were followed by death in six cases. Two children died in complete remission.
Flow cytometry methods
A flow cytometry study of DNA content was carried out on cell suspensions for 57 patients in accordance with the method already published. 19 Briefly, ethanol-fixed cells were stained with propidium iodide after ribonuclease A III (Sigma, St Louis, MO, USA) treatment. The stained cells were analyzed on a FACscan flow cytometer (Becton Dickinson, San Jose, CA, USA). The discrimination between G1 doublets and G2 cells was achieved by correlated measurements of pulse area and peak of red fluorescence signal. For each sample, 10 000 cells were analyzed. The percentages of cells in the cell cycle phases G0/G1, S and G2+M were calculated according to the R-FIT model (software provided by the manufacturer). Ploidy was determined by flow cytometry and controlled by cytogenetics (in one case, ploidy was determined only by cytogenetics). Lymphoblasts were diploid in 33 cases, hyperploid in 23 cases, and hypoploid in two cases.
Protein studies p16
ink4a was analyzed in all 58 cases and compared to the expression of other cell cycle regulatory proteins.
Cell samples were lysed and 70 g of proteins were separated electrophoretically in a 12% SDS-polyacrylamide gel(7.5% SDS polyacrylamide gel for pRb) and transferred to nitrocellulose membrane in a semi-dry system as previously described. 17 Upon completion of transfer, Ponceau S staining was performed to verify that an equal amount of protein was present in all lanes. 20 To ensure independence of expected variations between different ALL groups from differences resulting from gel and blot preparations, we ran a sample of Reh-6 cell line as an internal control. For p16 ink4a , the HeLa cell line was used as internal control.
The membranes were probed with the following antibodies: mouse monoclonal anti-p16 ink4a (1:2000) , anti-pRb (1:500), mouse monoclonal IgE anti-cyclin A (1:1000) from PharMingen (San Diego, CA, USA); mouse monoclonal antip34 cdc2 (1:500), anti-cyclin B (1:500), anti-cyclin E (1:250), anti-p53 (1:500) and rabbit polyclonal anti-cdk2 (1:500), anticdk4 (1:2000), anti-cdk6 (1:1000), anti-cyclin D3 (1:250), anti-p27
Kip1 (1:1000) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); mouse monoclonal anti-p21
Waf1 (1;250) from Amersham (Little Chalfont, UK), anti-Bcl2 (1:500) from Dakopatts (Copenhagen, Denmark). The membranes were then incubated with biotinylated rabbit anti-mouse immunoglobulin antibody (Dakopatts), biotinylated goat anti-rabbit immunoglobulin antibody (Sigma) or biotinylated rat antimouse IgE antibody (Southern Biotechnology Associates, Birmingham, AL, USA). In order to confirm the similarity of specimen quality a labeling of ␤-actin (monoclonal antibody from Serotec) was realized. The final step was incubation with streptavidin-biotinylated horseradish peroxidase complex (Amersham) and development with an enhanced chemoluminescence (ECL) detection system (Amersham).
The total intensity of the bands was measured by densitometry with correction for the background gray labelling of the lanes with a Quantimet 570 image analyzer (Leica, Cambridge, UK) (Centre Commun de Quantimètrie, Claude Bernard University Lyon I). Numerical values of sample signals were given as arbitrary units (AU). A.U. were calculated by dividing the numerical value of a sample signal by that of the signal from internal positive control on the same blot.
In addition, cdk1 and pRb expression were also analyzed qualitatively, ie the presence of slower migrating supplementary bands, corresponding to phosphorylated isoforms, was recorded.
Reverse transcription (RT)-PCR assay
Ink4a mRNA expression was studied in 42 out of the 58 cases for which we had enough cell material.
Total RNA was extracted from ALL cell samples by a guanidinium-thiocyanate-phenol/chloroform procedure using RNA Plus(Bioprobe Systems, Montreuil, France). Semi-quantitative RT-PCR of Ink4a was performed in accordance with the 'Primer-Dropping' method described by Wong et al 21 with coamplification of GAPDH as internal control in each sample. Primers for GAPDH were dropped into the reactions starting from the 16th-cycle, during the denaturation step, and the PCR amplification was continued for 25 cycles. The number of cycles was defined on previous experiments in order to remain in independent exponential amplification for both templates. Negative controls were realized in order to detect contaminations, without addition of reverse transcriptase and with water instead of RNA. To ensure independence of expected variations between different ALL groups from differences resulting in reverse transcription and amplification, we ran a sample of HeLa cell line as an internal control in each set of RT-PCR. Aliquots of PCR reaction products were electrophoresed through 2% agarose gels containing 0.5 g/ml ethidium bromide. Gels were illuminated with UV light, photographed using a numeric Kodak Camera (Eastman Kodak Company, Rochester, NY, USA) and quantified using the EDAS software from Kodak. Numerical values of sample signals were given as AU. A.u. were calculated by dividing the numerical value of a sample signal by that of the signal from Hela cell-positive control on the same RT-PCR set (each divided by the value of the coresponding GAPDH internal control).
The sequences of human ink4a and GAPDH primers were as described by Yamada et al 22 and Wong et al. 21, 23 Primer sequences for Ink4a were 5′-AGCATGGAGCCTTCGGCTGACT-3′ (exon 1 ␣); 5′-GACCTTCCGCGGCATCTATGC-3′ (exon 2) and for GAPDH 5′-CGGAGTCAACGGATTTGGTCGTAT-3′; 5′-AGCCTTCTCCATGGTGGTGAAGAC-3′. The length of PCR products expected were 430 and 306 bp, respectively.
Statistical methods
The analysis was based on non-parametrical methods: Spearman rank correlation coefficients, and Kruskall and Wallis test. Variable distribution was summarized by box plot representation showing (1) the median, (2) the 25th and the 75th percentile corresponding to each extremity of the box, (3) the smallest and the largest observed value that is not outlier (drawn as 'whiskers'), and (4) the outlier (circle) and extreme (star) values.
The prognostic value of the biological variables studied were analyzed by univariate analysis. We chose as cut-off point the median of the distribution for most variables (CDK4, CDK6, p21 waf1 , bcl-2). For WBC, three groups of patients were defined: (1) under 10 G/l, (2) over 100 G/l, and (3) between these two values. For p16 ink4a protein, three groups of patients were also considered: (1) with p16 ink4a equal 0, (2) with p16 ink4a superior to the median value, 0.210 AU, obtained in cases expressing the protein, and (3) with p16 ink4a between these two values. For the mRNA, three groups were also defined: (1) ink4a mRNA equal to 0, (2) ink4a mRNA over the 0.75 quartile value, and (3) between these two values. Survival curves were estimated by the Kaplan-Meier method. The significance of a survival difference observed between groups was assessed with the log-rank test and the Tarone and Ware test. A multivariate analysis was performed using the Cox model with the forward stepwise procedure. The analysis was performed with SPSS Statistical Software (SPSS, Chicago, IL, USA).
Results
Expression of p16 ink4a in ALL according to immunological phenotype
A strong positive correlation was found between p16 ink4a mRNA and protein expression (42 cases, r = 0.80, P Ͻ 0.00001) and this is in agreement with the previously described transcriptional regulation of the human ink4a gene. 7, 24 Protein and mRNA were not found in 12 cases (seven T cell and five B lineage ALLs) out of the 42 cases studied at both expression levels. The protein was never observed when the corresponding mRNA was not found. In three B lineage ALL cases, the protein was at 0 while mRNA was weakly expressed in two cases (0.184 and 0.09) and highly in one case (0.86 AU). A highly expressed protein was associated with a high expression of mRNA (Figure 1) .
Among the 58 cases studied for protein expression, 43 ALLs were B lineage ALLs and 15 T cell ALLs. The median and extreme values of the proteins studied, biological data concerning cell proliferation (S and S+G2/M fractions), and tumor burden (WBC) according to immunological phenotype are indicated in Table 1. p16 ink4a expression varied significantly according to immunological subtypes (P Ͻ 0.0001) (Figure 2 ). p16 ink4a protein was not observed in 13 out of the 15 T cell ALLs, and in 10 out of 43 B lineage ALLs (10 early pre-B ALLs). p16
ink4a was expressed in all the six early early pre-B ALLs and reached the highest levels in this group. Among the proteins studied, beside p16 ink4a , p21
waf1 and Bcl2 were significantly more strongly expressed in B lineage than in T-ALLs (P Ͻ 0.001). p21
waf1 was not found in three T-ALLs and was very low in the 12 remaining T cell cases (Table 1) ; CDK4 was also higher in B lineage ALLs compared to T cell ALLs (P = 0.025). Inversely to p16 ink4a , CDK1 and CDK6 were significantly higher in T than in B lineage ALLs (P Ͻ 0.002 and P Ͻ 0.02, respectively) ( Figure 2 ).
Cell proliferation and p16 ink4 expression
No correlation could be observed between p16 ink4a protein (or mRNA) expression and the percentage of cells in S or S+G2+M phases, nor with CDK1 or cyclin A, two cell cycle regualtory proteins known to be linked with cell proliferation. 25, 26 p16 ink4a expression did not significantly vary according to the phosphorylation levels of CDK1. Disease-free survival curves in the 57 ALL patients stratified according to p16 ink4a expression; numerical values are given in Table 3 ; (a) p16 ink4a Ͼ 0 and below the median value; (b) p16
ink4a above the median value.
p16 ink4a expression and disease-free survival (DFS) in ALLS
Complete remission was obtained in all the 57 cases treated, and a relapse occurred in eight of these cases.
The three groups of patients, as previously defined according to p16 ink4a expression, were considered for univariate DFS analysis. A significant difference was observed for the DFS according to the level of p16 ink4a (57 cases, P = 0.0165) ( Figure 3 and Table 2 ). The shortest DFS was obtained for the enhanced p16 ink4a expression group (16 patients, five relapses), contrasting with the good evolution of patients expressing the CKI at low level (18 patients, no relapse); the absence of p16 ink4a expression was associated with a medium evolution (23 cases, three relapses). This prognostic value was retained when the patient population was restricted to the B lineage ALL (43 cases, P Ͻ 0.025) or to the VHR treatment group (20 cases, P Ͻ 0.03).
Although not significant, the ink4a mRNA high level group was also associated with the poorest prognosis (42 cases, P = 0.118). p16 ink4a protein expression was included in a multivariate Cox regression analysis with known prognostic factors: therapeutic regimens (which take into account poor cytogenetic features, ie t(9;22), t(4;11), t (1;19) ), corticoid sensitivity, WBC level, ploidy and CDK4. On this series of 57 patients, in univariate analysis, DFS was shorter with VHR treatment (P = 0.015), corticoid resistance (P = 0.015), hyperleukocytosis (P = 0.04), diploidy (P = 0.085) and high CDK4 level (P = 0.058) ( Table 2 ). The multivariate analysis using the forward stepwise method was performed on the 57 patients. The kind of treatment and p16 ink4a protein expression appeared to be the best prognostic predictors and were the only variables retained in the model (Table 3) .
Relationships between enhanced p16 ink4a expression and biological characteristics of ALLs
In order to understand the reasons for the prognostic value of p16 ink4a , we sought out the existence of distinctive clinical or metabolic features associated with each of the three p16 ink4a subgroups presented in Table 4 . Hyperleukocytosis and diploidy (two factors of poor prognosis) were more frequently observed when p16 ink4a was not found than in cases expressing this protein (P = 0.002 and P = 0.0075, respectively). No difference in p16 ink4a expression was observed according to glucocorticoid sensitivity or according to the kind of treatment. No peculiar cytogenetic characteristics could be retained for the poor prognostic group: we may point out that the two patients with a t(4;11)(q21;q23) translocation highly expressed p16
ink4a
. One patient presenting a t(9;22) translocation also expressed p16 ink4a at a high level, while the other patient showing this translocation belongs to the low p16 ink4a expression group. No correlations could be found between p16 ink4a and pRb protein expression or between p16 ink4a expression and pRb phosphorylation level. Among all proteins analyzed in the whole group of patients, few proteins were correlated to p16 ink4a expression: p21 waf1 (r = 0.66), CDK4 (r = 0.51) and bcl2 (r = 0.55) (P Ͻ 0.0001). Enhanced expression of p16 ink4a was associated with a high level of these three proteins ( Figure 4 , Table 4 ). These significant positive correlations were maintained when the analysis was restricted to the 43 B lineage ALLs. Furthermore, comparison between the three groups defined by the level of p16 ink4a expression showed a significant difference not only for p21 waf1 , CDK4 and bcl-2, but also for CDK6, which was significantly under expressed when p16
ink4a was present at a low level ( Figure 4 , Table 4 ). In univariate analysis, p21 waf1 , CDK6 and Bcl2 The cut-off for determining low and high level of expression is the median in cases expressing p16 ink4a (0.210 AU). We only report here the proteins (median (M), extreme values (EV)) whose expression showed a significant difference between groups (expression is given in arbitrary units). Differences between groups are analyzed by 2 test for dichotomic variables and by Kruskall and Wallis test for continuous variables. F, female; M, male; WBC, white blood cells; D, diploid; An, Aneuploid; VHR, very high risk; CS, corticoid sensitivity; N, number of cases.
Figure 4
Box plot representation of cell cycle regulatory proteins showing significant differences according to p16 ink4a expression groups. (1: p16 ink4a = 0; 2: p16 ink4a Ͼ 0 and below the median value; 3: p16 ink4a above the median value).
expression did not have a significant impact on prognosis. On the contrary, a high level of CDK4 was associated with a short DFS for all 57 cases (P = 0.058) as well as for B lineage ALL (P Ͻ 0.04) ( Figure 5 and Table 2 ). This prognostic value was not retained in a multivariate Cox model analysis with other known prognostic factors.
Discussion
Several proteins involved in cell cycle regulation, such as D-type cyclins 27, 28 as well as their catalytic sub-unit, CDK4 29 present an oncogenic activity. On the contrary, numerous data support the notion that p16 ink4a is a tumor suppressor. 30, 31 It is then surprising that our results show a significant unfavorable course for childhood ALL presenting an enhanced p16 ink4a expression. However, analysis of prognosis according to the presence of homozygous deletion failed to demonstrate a worse evolution for p16 ink4a −/− cases in children. 14, 15 Furthermore, Volm et al, 32 in an immunocytochemistry study showed that the absence of p16 ink4a expression seemed to be associated (while not statistically significant) with a prolonged relapse-free disease. The interest of these results is reinforced by recent findings in breast cancer showing an identical poor prognostic value of p16 ink4a high p16 ink4a and prognosis of ALL Y Mekki et al 187
Figure 5
Disease-free survival curves in the 57 ALL patients stratified according to CDK4 expression; numerical values are given in Table 3 ; (a) CDK4 below; (b) CDK4 above the median value.
expression. 33 We present a differential analysis according to the p16 ink4a mRNA and protein expression, and both approaches gave concordant results: the shortest DFS was obtained for the enhanced p16 ink4a expression group, which contrasts with the good evolution of patients expressing the CKI at low levels. This finding did not imply an oncogenic role for p16 ink4a , but the increase in protein expression might reflect the convergence of several unfavorable metabolic conditions.
In order to better understand this metabolic context, we studied, besides p16 ink4a , cell cycle variables (S and S+G2+M) through the analysis of DNA content, the expression of other CKIs (p21 waf1 and p27
kip1
), of CDKs (CDK1, CDK2, CDK4, CDK6), of cyclins (cyclin D3, E, A), and of cell cycle-related proteins (pRb, p53 and bcl-2). No correlation was found between the percentage of cells in S or S+G2+M and p16 ink4a expression. As previously shown in another study, 17 CDK1 and CDK6 are significantly more expressed in T cell ALLs. On the contrary, p16 ink4a is significantly higher in B lineage than in T cell ALLs, reaching the highest values in the least differentiated (early early pre-B) cases. p16 ink4a mRNA and protein are not expressed in most T cell ALLs, as expected, because of the known frequency of homozygous deletion in this form of ALL. Among all proteins studied, only p21 waf1 , bcl-2 and CDK4 were statistically correlated to p16 ink4a expression and were significantly higher in B lineage than in T cell ALLs.
Bcl-2, p21 waf1 and p16 ink4a are implicated in prolonged cell survival and in senescence. Overexpression of the anti-apoptotic bcl-2 oncoprotein has been shown to be associated with a prolonged survival of B lineage ALL cells and may contribute to leukemogenesis by prolonging the lifespan of progenitor cells unable to differentiate further. 34 p21 waf1 also accumulates in near-senescent cells, 35 and it was originally identified via this phenomenon. 36 This up-regulation of p21 waf1 by senescence is independent from p53. 36 Similarly, p16 ink4a mRNA and cellular protein levels gradually rise in near-senescent and senescent human diploid fibroblasts. An apparent overexpression of p16 in pRb-negative cell lines is caused by the loss of repression by pRb but also by an increase in the number of cell population doubling. 7 This CKI was shown to be complexed, in senescent human fibroblasts, to both CDK4 and CDK6, inhibiting their kinasic activity on pRb and taking part in the G1 accumulation of aging cells. 37 These data suggest that ALLs with enhanced expression of p16 ink4a show a near-senescent phenotype. However, we also observed, in these cases, an increased level of CDK4 (and of CDK6) while, in the context of senescence, a downregulation of CDK4 is expected. 38 This increase in kinases regulating G1 phase may favor the progression through G1 phase and finally cell multiplication. Such a situation may be compared to the elevated p16 ink4a expression in SV40-transformed primary mouse fibroblasts approaching their finite lifespan in culture. In these cells there were no apparent differences in the status of cyclin D1-CDK4 complexes irrespective of their age or pRb function. Thus, the observed accumulation of p16 ink4a does not occur as a simple consequence of growth arrest associated with senescence, since it is apparent in fibroblasts that escape senescence as a result of T-Ag function. 39 Indeed, the sole prolonged cell life did not seem sufficient to explain the implication of p16 ink4a as a prognostic factor. Bcl-2 did not show significant statistical prognostic value in this series. A similar result, for bcl-2, was demonstrated recently on a large series of childhood ALLs. 40 Other explanations than a simple prolonged cell life could be proposed to explain our results. A high expression of p21 waf1 leads to a decrease in chemotherapy sensitivity 41 and this effect might be raised by an increase in p16 ink4a expression. 42 Furthermore, a concomitant high expression of the oncogenic protein, CDK4, and of CDK6 might amplify the leukemic advantage by sequestering p16 ink4a or other CKIs, and thus favoring the progression through G1 phase. We have shown the negative influence of a high CDK4 expression on event-free survival, and Volm et al, 32 with another methodology, had the same result. Therefore, the bad prognosis of an enhanced expression of p16 ink4a might be related both to a prolonged leukemic cell lifespan and to a growth advantage.
Nevertheless, we can point to the very good prognosis associated with the expression of p16 ink4a at a low level. In these ALLs, we also found a low and moderate expression of CDK6 and CDK4, respectively. This metabolic context may favor the p16 ink4a tumor suppressor capability. Conversely, we found that the absence of p16 ink4a expression is associated with a significantly more frequent diploidy and hyperleukocytosis (two factors of poor prognosis) and a medium course of the disease. So far, no association has been found between the presence of homozygous deletion of Ink4a gene and prognosis in childhood ALLs. 14, 15 This result may be explained by the prognostic heterogeneity of the group with Ink4a expression (which includes all cases with low and enhanced p16 ink4a expression): both groups, with or without homozygous deletion, may present then, an intermediary disease-free survival. This interpretation is supported by the poor prognostic value of Ink4a homozygous deletion observed in a subgroup of standard risk adult ALLs where very aggressive ALLs were excluded. 43 The three biological situations involving p16 ink4a absent or expressed at low or high levels, may be taken into consideration when attempting to understand the strong prognostic value of this protein expression in a multivariate survival analysis. We hypothesize that the differential expressions of p16 ink4a may reflect the different mechanisms involved in the neoplastic process, ie deregulation of cell multiplication and prolonged blast lifespan, and perhaps may participate in them.
